We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current EGRX market cap is 50M. The company's latest EPS is USD 2.7444 and P/E is 1.40.
| Quarter End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 74.14M | 65.9M | 60.7M | 66.31M | 64.65M |
| Operating Income | 503k | 9.46M | -2.93M | 11.77M | 10.3M |
| Net Income | -9.45M | -7.13M | 8.17M | 5.75M | 5.16M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 213.31M | 195.89M | 187.8M | 171.55M | 316.61M |
| Operating Income | 38.56M | 21.82M | 32.95M | 2.77M | 80.96M |
| Net Income | 31.9M | 14.31M | 11.99M | -8.63M | 35.64M |
| Quarter End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 381.76M | 386.45M | 406.16M | 414.18M | 404.82M |
| Total Liabilities | 143.77M | 154.67M | 172.6M | 171.33M | 152.78M |
| Total Equity | 237.98M | 231.78M | 233.56M | 242.85M | 252.04M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 238.6M | 254.55M | 253.19M | 253.73M | 406.16M |
| Total Liabilities | 77.84M | 75.38M | 67.18M | 77.28M | 172.6M |
| Total Equity | 160.76M | 179.17M | 186.01M | 176.45M | 233.56M |
| Quarter End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 26.38M | 13.14M | 50.7M | -33.51M | -33.64M |
| Investing | -75.58M | -86.82M | -86.83M | -12.56M | -12.56M |
| Financing | -11.89M | -8.6M | 13.79M | 12.65M | 6.24M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 52.38M | 55.99M | 49.5M | 28.22M | 50.7M |
| Investing | -133k | -777k | -18.25M | -5.32M | -86.83M |
| Financing | -88.12M | -24.23M | -37.87M | -28.39M | 13.79M |
| Market Cap | 50M |
| Price to Earnings Ratio | 1.40 |
| Price to Sales Ratio | 0.16 |
| Price to Cash Ratio | 0.9 |
| Price to Book Ratio | 0.21 |
| Dividend Yield | - |
| Shares Outstanding | 12.99M |
| Average Volume (1 week) | 130.67k |
| Average Volume (1 Month) | 165.9k |
| 52 Week Change | -80.78% |
| 52 Week High | 23.52 |
| 52 Week Low | 3.2101 |
| Spread (Intraday) | 1.41 (28.6%) |
| Company Name | Eagle Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.eagleus.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
